Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kaplan-Meier Approach01:24

Kaplan-Meier Approach

98
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
98
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

97
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
97
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

120
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
120
Probability Laws01:49

Probability Laws

40.1K
Overview
40.1K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

12.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.4K
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

150
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
150

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient and Physician Global Disease Assessments in Systemic Sclerosis: Distinct and Complementary Constructs.

Arthritis care & research·2026
Same author

Does the ACR/EULAR Total Improvement Score Reflect How Individuals With Autoimmune Inflammatory Myopathies Feel and Function?

The Journal of rheumatology·2026
Same author

Distinct Systemic Sclerosis Phenotypes Related to Ethnicity: An Opportunity to Personalize Care?

Arthritis care & research·2026
Same author

Mouse models of immune-related adverse events: progress, challenges, and opportunities.

Trends in cancer·2026
Same author

Umbilical cord mesenchymal stromal cells for respiratory complications of COVID-19 infection (ProTrans): phase II randomized clinical trial.

Cytotherapy·2026
Same author

Discussion on ''Nonparanormal Adjusted Marginal Inference'' by Susanne Dandl and Torsten Hothorn.

Biometrics·2026

Related Experiment Video

Updated: Jun 6, 2025

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

10.9K

A Bayesian adaptive feasibility design for rare diseases.

Maureen M Churipuy1, Shirin Golchi1, Marie Hudson2

  • 1Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada.

Contemporary Clinical Trials Communications
|December 2, 2024
PubMed
Summary

This study introduces a Bayesian design using pilot data to predict clinical trial sample size feasibility. This approach enhances efficiency, especially for rare disease trials.

Keywords:
BayesianClinical trialFeasibilityPilot trialRare diseaseRecruitmentStudy design

More Related Videos

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
00:06

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.6K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.6K

Related Experiment Videos

Last Updated: Jun 6, 2025

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

10.9K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
00:06

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.6K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.6K

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Bayesian Methods

Background:

  • Assessing clinical trial feasibility, particularly sample size achievement, is crucial before study initiation.
  • Traditional methods may not adequately predict sample size success for complex trials.

Purpose of the Study:

  • To present a novel Bayesian design for predicting clinical trial sample size feasibility.
  • To demonstrate the utility of this design in planning Phase III trials, especially for rare diseases.

Main Methods:

  • A Bayesian framework is proposed, utilizing pilot study data.
  • A predictive model based on the Gamma-Poisson distribution is outlined to estimate target sample size.
  • The design is illustrated using a simulation study for a Phase III trial in mild systemic sclerosis.

Main Results:

  • The proposed Bayesian design effectively predicts sample size feasibility.
  • The Gamma-Poisson distribution model provides a robust method for sample size prediction.
  • The predictive design shows significant potential for improving the efficiency of rare disease clinical trials.

Conclusions:

  • The presented Bayesian design offers a valuable tool for enhancing clinical trial planning and feasibility assessment.
  • This methodology can lead to more efficient and successful rare disease clinical trials.
  • Accurate sample size prediction is key to optimizing resource allocation and trial outcomes.